Milestone Pharmaceuticals Inc. 8-K

What Happened

• On January 26, 2026, Milestone Pharmaceuticals, Inc. (MIST) announced in a Form 8-K (Item 8.01) and accompanying press release that CARDAMYST (etripamil) nasal spray is available in the United States for the management of paroxysmal supraventricular tachycardia (PSVT). The press release is filed as Exhibit 99.1 and is incorporated by reference into the 8-K.

Key Details

• Filing type and date: Current Report on Form 8-K, Item 8.01 (Other Events), dated January 26, 2026.
• Product: CARDAMYST (etripamil) nasal spray — indicated for management of PSVT in the U.S.
• Exhibit: Press release announcing availability filed as Exhibit 99.1 to the 8-K.
• The filing does not include financial results, sales figures, or operational metrics.

Why It Matters

• This 8-K provides a material commercial update: the company is announcing U.S. availability of its marketed product, which is a key milestone in commercialization.
• Investors should note the announcement itself contains no revenue or usage data; follow-up disclosures (press releases, earnings reports, or sales updates) will be needed to assess commercial impact.